Phase
Condition
Epilepsy (Pediatric)
Epilepsy
Treatment
Placebo
Ketamine
Midazolam
Clinical Study ID
Ages 6-16 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Age from 6 month to 16 years.
Generalized convulsive status epilepticus, defined as > 5 minutes of clinicallyobserved continuous or recurrent generalized, tonic-clonic seizure activity withoutregaining of consciousness.
Exclusion
Exclusion Criteria:
Failure to obtain informed consent.
Previous treatment with any antiseizure medication for the presenting seizureepisode.
Hypertension
Alcohol intake
Conditions associated with increased intracranial pressure (e.g., central nervoussystem mass lesions, hydrocephalus)
Glaucoma
Known allergy or contraindications to any of the study drugs.
End-stage kidney disease.
End stage liver disease
Arrhythmia, severe heart disease, or pulmonary hypertension.
Hyperthyroidism
Pheochromocytoma
Hypoglycemia or hyperglycemia.
Inborn errors of metabolism.
Known or suspected psychiatric disorder.
Failure to obtain intravenous access in the first 5 minutes of stabilization phase.
Cessation of seizures during the stabilization phase (0 - 5 minutes).
Traumatic brain injury.
Study Design
Study Description
Connect with a study center
Sohag University Hospital
Sohag, 82524
EgyptSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.